No NOAEL (no tox studies); tissue cross-reactivity limited to CD19+ B cells in lymphoid tissues, no off-target binding
“The data indicate that human tissue cross reactivity with the CAT19 CAR binding domain was consistent with the expected profile of CD19 expression on B lymphocytes.”
✓ VerifiedFDA pharmacology/toxicology review, p. 11Source ↗